Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabolic syndromes and malignant transformation: where the twain shall meet.

Science translational medicine - 20 Oct 2010

Bhagwat Neha, Levine Ross L

Abstract excerpt

Recurrent somatic mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes that result in the accumulation of D-2-hydroxyglutarate (D-2-HG) have been identified in malignant gliomas and in acute myeloid leukemia (AML). However, the function of this metabolite in normal and malignant tissues remains uncertain. A report in the current issue of Science describes a germline IDH2 mutation in a subset of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transformation, Neoplastic
Share to IDH2 gene
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutarates

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Metabolism, Inborn Errors

Share to Mutation

Source

Identifiers

PMID: 20962328
DOI: 10.1126/scitranslmed.3001669

Genes

IDH2
IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabolic syndromes and malignant transformation: where the twain shall meet.PMID 20962328Read ↗

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.Semantic proximity Read ↗

Metabolic consequences of oncogenic IDH mutations.Semantic proximity Read ↗

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches.Semantic proximity Read ↗

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.Semantic proximity Read ↗

IDH1 mutations in gliomas: when an enzyme loses its grip.Semantic proximity Read ↗

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.Semantic proximity Read ↗

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.Semantic proximity Read ↗

Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation.Semantic proximity Read ↗

Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic StrategiesSemantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.